Summary: Biosimilars present unique development challenges, but the Mass Spectrometry-based Multi-Attribute Method (MAM) offers a deeper understanding of molecule attributes by analyzing multiple factors in a single workflow. This advanced technique ensures efficient analysis, reduces variability, and maintains the consistent quality and safety of biosimilars. Biological medicines (biopharmaceutical) have transformed the way we treat chronic … Continue reading Navigating the Complexities of Peaks and Attributes in Biopharmaceuticals Using Mass Spectrometry-based Multi-Attribute Method (MAM)
Bridging the Gap in Diabetes Care by Upskilling Nurses in Ethiopia
Diabetes continues to pose a significant global health challenge, particularly in low- and middle-income countries (LMICs) like Ethiopia. With a prevalence rate of 2–3%, Ethiopia ranks among the top four countries in sub-Saharan Africa for diabetes cases, contributing to nearly 2% of all deaths in the country. Despite these alarming statistics, the nation faces a … Continue reading Bridging the Gap in Diabetes Care by Upskilling Nurses in Ethiopia
Biocon Biologics Opens North America Headquarters in New Jersey’s Biopharma Corridor
Biocon Biologics proudly celebrated a significant milestone with the official opening of its new North America headquarters in Bridgewater, New Jersey, on Friday, September 13. This occasion also marked the Company’s first-year anniversary in the region, further solidifying its commitment to providing high-quality, affordable biosimilar medicines to patients in North America and across the globe. … Continue reading Biocon Biologics Opens North America Headquarters in New Jersey’s Biopharma Corridor
Biocon Biologics off to a solid start in Q1 FY25, powered byproduct sales & market shares
The successful integration of the acquired Biosimilars business dominated the Biocon Biologics growth story last year. In fiscal year 2024-25 (FY25), we have turned our focus to consolidating the acquired business and paving the way for future growth. Our performance in the first quarter of FY25 gives us confidence that we are on the right … Continue reading Biocon Biologics off to a solid start in Q1 FY25, powered byproduct sales & market shares
Biocon Biologics Commemorates International Women’s Day 2024 with a Focus on Diversity & Inclusion
Agnostic of the gender, leadership qualities come from passion, vision, and foresight for ushering meaningful changes for a better tomorrow. For a leader to lead, it is the leadership quality that takes precedence over the binary of gender. Celebrating Women’s Day and Making Each One Count In a display of great camaraderie and participation, Biocon … Continue reading Biocon Biologics Commemorates International Women’s Day 2024 with a Focus on Diversity & Inclusion
Consolidation of acquired business fuels Biocon Biologics’ growth trajectory
Biocon Biologics’ (BBL) revenues for Q1 FY24 saw an over 100% year-on-year growth, driven by the consolidation of the biosimilars business acquired from Viatris, as well as higher sales of commercialized products that is reflected in their market share gains in U.S. & Europe. The robust performance this quarter has given Biocon Biologics the impetus … Continue reading Consolidation of acquired business fuels Biocon Biologics’ growth trajectory
Delivering on ‘Power of One’; Biocon Biologics starts FY24 on a Strong Footing with 2-fold Revenue Jump in Q1
Biocon Biologics Limited (BBL) got off to a promising start to FY24 with an over two-fold increase in first-quarter revenues, truly reflecting the “Power of One” derived from the Company's transformative acquisition of the global biosimilars of its long-term partner Viatris. Driven by market share gains for its commercialized biosimilars in key markets and the … Continue reading Delivering on ‘Power of One’; Biocon Biologics starts FY24 on a Strong Footing with 2-fold Revenue Jump in Q1
Biocon Biologics Ends FY23 on a $1 billion Annual Revenue Trajectory
Biocon Biologics Ltd (BBL) has ended financial year 2023 (FY23) on a high. The year marks an inflection point in its value creation journey as the acquisition of partner Viatris’ biosimilars business has catapulted the company into the global big league. BBL more than doubled its revenue on a YoY basis to Rs 2,102 crore … Continue reading Biocon Biologics Ends FY23 on a $1 billion Annual Revenue Trajectory
Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
The world is just emerging from the economic impact of the COVID-19 pandemic. The people who suffered the economic fallout of the pandemic as their incomes shrunk, urgently need of access to cheaper drugs. This has been the case not only in the emerging markets, but also in the developed countries. Generics and biosimilars which … Continue reading Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
The global economy is in its steepest slowdown since 1970. The IMF has forecast that global economic growth will slow to 3.2% in 2022 and 2.9% in 2023 from 6.1% in 2021. While high inflation continues to make headlines across the globe, spiralling healthcare costs need to be addressed. Biosimilars, which provide affordable access to … Continue reading Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
Biocon's Chairperson Kiran Mazumdar-Shaw in a QnA with FE’s Srinath Srinivasan, talks about the bold moves Biocon Biologics is making since 2021, including the recent acquisition of Viatris’ global biosimilars business, which will provide it a direct entry into the US & Europe with the acquired commercial engine in developed and key emerging markets. This … Continue reading Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
Biocon developing 20 biosimilar products for global markets
India's premier biopharmaceutical company Biocon is working on a pipeline of 20 biosimilar drugs or similar but not identical copy of biologic medicines, to tap the upcoming huge opportunity. Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products. It has biosimilars in oncology like … Continue reading Biocon developing 20 biosimilar products for global markets
‘Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines’
Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd., says the structure of the strategic alliance with Serum Institute Life Sciences provides Biocon Biologics with an asset light and accelerated entry into the often overlooked infectious diseases segment. Having established capabilities and a track record of success in biologics, Biocon Biologics’ foray into vaccines and antibodies for … Continue reading ‘Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines’
A Unique & Synergistic Alliance to Impact Global Health
Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd, have entered into a historic alliance to impact global health. This alliance will complement the strengths and resources of two leading Indian players in addressing inequitable access both in … Continue reading A Unique & Synergistic Alliance to Impact Global Health
A Blog by Biocon 